摘要
目的:探究吉非替尼与沙利度胺联用对非小细胞肺癌患者的临床疗效及其对癌胚抗原(CEA)和糖类抗原(CA125)水平的影响。方法:选取2014年2月—2016年2月间收治的非小细胞肺癌患者96例资料,采用随机数字表法将其分为观察组和对照组,每组48例;对照组患者予以吉非替尼治疗,观察组患者予以吉非替尼与沙利度胺联用治疗,比较两组患者治疗后的总有效率、用药期间不良反应发生率和生存率的差异,以及治疗前后血清CEA、CA125水平测得值的变化情况。结果:观察组患者治疗后的总有效率高于对照组(P<0.05);两组患者用药期间不良反应的发生率经组间比较其差异无统计学意义(P>0.05);观察组患者治疗后1年、2年生存率均高于对照组(均P<0.05);治疗后两组患者血清CEA、CA125水平测得值均低于治疗前(P<0.05),且观察组患者治疗后的血清CEA、CA125水平测得值均低于对照组(P<0.05)。结论:采用沙利度胺与吉非替尼治疗非小细胞肺癌患者的疗效较为显著,有效改善了血清CEA、CA125水平,提高了生存率。
Objective:To evaluate the clinical efficacy of Gefitinib combined with Thalidomide in patients withnon-small cell lungs cancer and its influence on carcinoembryonic antigen(CEA) and carbohydrate antigen(CA125)level. Methods:Data of 96 patients with non-small cell lung cancer admitted and treated from February 2014 to Febru-ary 2016 were selected and divided into observation group and control group by random number table method, 48 casesin each group. Patients in the control group were treated with gefitinib, and patients in the observation group were treat-ed with gefitinib combined with thalidomide. The total effective rate, incidence of adverse reactions and survival rate ofthe two groups after treatment were compared, and the changes of serum CEA and CA125 levels before and after treat-ment were also compared. Results:The total effective rate of the observation group was higher than that of the controlgroup(P<0.05). The incidence of dizziness, rash, pruritus, diarrhea and abnormal liver function between the observationgroup and the control group had no significant difference(P>0.05). After treatment, the serum CEA and CA125 levelsin the observation group and the control group were lower than those before treatment, and the observation group waslower than the control group(P<0.05). The 1 year survival rate and the 2 year survival rate of the observation groupwere all higher than those of the control group(P<0.05). Conclusion:The efficacy of thalidomide combined with gefi-tinib in patients with non-small cell lung cancer is relatively significant. The serum CEA and CA125 levels were effec-tively improved and the survival rate was increased.
作者
武乐
叶华姝
刘震天
WU-Le;YE Hua-Shu;LIU Zhen-Tian(Department of Pharmacy,Jiangxi Tumor Hospital,Nanchang 330029,China;Department of Thoracic Oncology,Jiangxi Tumor Hospital,Nanchang 330029,China)
出处
《抗感染药学》
2018年第12期2118-2121,共4页
Anti-infection Pharmacy
